TipRanks(@TipRanks):Oscar Health $OSCR price target raised to $49 from $39 at Barclays Barclays analyst Andrew Mok raised the firm's price target on Oscar Health to $49 from $39 and keeps an Overweight rating on the shares following the investor day. Oscar outlined a "credible path" to over $4 of earnings per share by 2029 and implied 2027 earnings over $3.00 versus the $1.92 Street estimate, the analyst tells investors in a research note. Barclays sees "significant growth ahead" for Oscar.

TipRanks

@TipRanks

Your source for breaking stock news! 55% OFF TIPRANKS PREMIUM 👉

加入 July 2012

1.7K 正在關注 44K 粉絲

TipRanks@TipRanks

2026.09.17 09:33

Oscar Health $OSCR price target raised to $49 from $39 at Barclays Barclays analyst Andrew Mok raised the firm's price target on Oscar Health to $49 from $39 and keeps an Overweight rating on the shares following the investor day. Oscar outlined a "credible path" to over $4 of earnings per share by 2029 and implied 2027 earnings over $3.00 versus the $1.92 Street estimate, the analyst tells investors in a research note. Barclays sees "significant growth ahead" for Oscar.